JAC Advance Access originally published online on June 10, 2005
Journal of Antimicrobial Chemotherapy 2005 56(2):349-352; doi:10.1093/jac/dki197
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In vitro activity of tigecycline against Bacteroides species
Department of Clinical Microbiology, Hospital Clínico San Carlos, 28040 Madrid, Spain
Received 3 March 2005; returned 4 May 2005; revised 19 May 2005; accepted 20 May 2005
* Corresponding author. Tel: +34-91-3303486; Fax: +34-91-3303478; E-mail: cbetriu{at}efd.net
Objectives: To ascertain the current susceptibility patterns of members of the Bacteroides fragilis group in our hospital and to assess the in vitro activity of tigecycline against these organisms.
Methods: A total of 400 non-duplicate clinical isolates of the B. fragilis group collected from 2000 to 2002 were studied. Susceptibility testing was performed according to the reference agar dilution method described by the NCCLS. The following antimicrobials were tested: tigecycline, clindamycin, metronidazole, chloramphenicol, cefoxitin, imipenem, amoxicillinclavulanate and piperacillintazobactam.
Results: All strains were susceptible to metronidazole and chloramphenicol. For clindamycin and cefoxitin, the overall susceptibility rates were 59.5% and 83%, respectively. Imipenem and piperacillintazobactam were the most active ß-lactam agents tested. Tigecycline inhibited 89.8% of the strains at a concentration of 8 mg/L with an MIC range of
0.01 to >16 mg/L. By comparing the MIC50 and MIC90 values of tigecycline among the various species of the group, B. fragilis, Bacteroides thetaiotaomicron and Bacteroides vulgatus were the most susceptible (MIC50/MIC90s of 0.51/8 mg/L).
Conclusions: Tigecycline exhibited activity against most isolates of the B. fragilis group tested. These results indicate that tigecycline may be useful in the treatment and prophylaxis of infections involving these organisms.
Keywords: susceptibility , glycylcyclines , Bacteroides fragilis group
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. M. Wexler Bacteroides: the Good, the Bad, and the Nitty-Gritty Clin. Microbiol. Rev., October 1, 2007; 20(4): 593 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Snydman, N. V. Jacobus, L. A. McDermott, R. Ruthazer, Y. Golan, E. J. C. Goldstein, S. M. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, et al. National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004 Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1649 - 1655. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3507 - 3513. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kasbekar Tigecycline: A new glycylcycline antimicrobial agent. Am. J. Health Syst. Pharm., July 1, 2006; 63(13): 1235 - 1243. [Abstract] [Full Text] [PDF] |
||||


